Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27701674 | 0.82 | CYP2C9 (0.46) | SCDCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL16398763 | 0.81 | GAA (0.51) | ALDH1A1LMNA | |
| SCHEMBL223124 | 0.78 | CYP2C9 (0.50) | SCDMAPTCYP2C9CYP2C19HTR2B | |
| SCHEMBL25610 | 0.76 | SCD (0.53) | SCDCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL25379 | 0.74 | MAPT (0.45) | SCDMAPTCYP2C9CYP2C19HTR2B | |
| SCHEMBL25380 | 0.74 | MAPT (0.45) | SCDMAPTCYP2C9CYP2C19HTR2B | |
| SCHEMBL12881276 | 0.73 | BLM (0.57) | SCDCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL27701738 | 0.73 | CYP2C9 (0.60) | SCDCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL27701741 | 0.71 | SCD (0.59) | SCDCYP2C9CYP2C19HTR2BMAPK14 | |
| SCHEMBL13983799 | 0.71 | SCD (0.62) | SCDCYP2C9CYP2C19HTR2BMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1830837-B1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY STEAROYL-COA DESATURASE ENZYMES | XENON PHARMACEUTICALS INC (CA) | 2013-09-04 | — | — | EP | disclosed |
| US-7919496-B2 | 5-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]-[1,3,4]thiadiazole-2-carboxylic acid ethyl ester; metabolic disorders type II diabetes, impaired glucose tolerance, insulin resistance, obesity, fatty liver, non-alcoholic steatohepatitis, dyslipidemia and metabolic syndrome; cardiovascular disorders | XENON PHARMACEUTICALS INC. (CA) | 2011-04-05 | — | — | US | disclosed |
| EP-2289510-A1 | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes | Xenon Pharmaceuticals Inc. (CA) | 2011-03-02 | — | — | EP | disclosed |
| US-20080108629-A1 | Heterocyclic Derivatives for the Treatment of Diseases Mediated by Stearoyl-Coa Desaturase Enzymes | XENON PHARMACEUTICALS INC. (CA) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108629-A1 | Heterocyclic Derivatives for the Treatment of Diseases Mediated by Stearoyl-Coa Desaturase Enzymes | SCD, SCD5, ECHS1 | SCD 1/4885MAPT 4243/4885CYP2C9 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.